Mental Health & Neuroscience

MDMA-Assisted Therapy After the Rejection: Where the Work Stands

A Phase 3 programme produced some of the largest effect sizes in modern psychiatry. The regulator was not persuaded — and what it objected to was not, in the main, the effect size.

Revuelt Health · August 9, 2026 · 10 min read

Joe Dispenza and the Evidence Behind the Retreat

A week of meditation, an audience of thousands, and claims about gene expression and healing. We read the peer-reviewed record rather than the testimonials.

Revuelt Health · July 27, 2026 · 10 min read

The New Wave of Psilocybin Trials for Treatment-Resistant Depression

Phase II results were striking enough to sustain a decade of interest. The larger trials now underway will decide whether the effect holds outside a small, carefully selected room.

Revuelt Health · July 21, 2026 · 9 min read

TMS Therapy, and the Five-Day Protocol That Changed the Conversation

Magnetic stimulation of the prefrontal cortex has been FDA-cleared for depression since 2008. Stanford's accelerated version compressed six weeks into five days.

Revuelt Health · July 18, 2026 · 9 min read

Updated August 5, 2026

Ibogaine and the Hard Problem of Addiction: What the Research Actually Shows

Observational data on opioid withdrawal is genuinely interesting. The cardiac risk profile is genuinely serious. Both facts have to be held at once.

Revuelt Health · July 14, 2026 · 11 min read

Ketamine Clinics Are Multiplying. The Standard of Care Has Not Caught Up.

The drug works quickly for some people with severe depression. What happens around the infusion varies enormously from clinic to clinic.

Revuelt Health · June 9, 2026 · 7 min read